KAEDI Medical Completes Nearly RMB 100 Million Series A and A+ Financing to Accelerate Clinical Development and IND Filings of Core CAR-T Pipeline

On March 10, 2022, Kaidi Medical (formerly "Kaidi Biotech") officially announced the completion of nearly RMB 100 million in Series A and A+ financing. This round of financing was jointly invested by "Longmen Capital" and "Kangyuan Huiying," among others, to deepen cooperation with strategic partners such as Porton Biologics and accelerate the IND application process in both China and the U.S. for multiple core pipelines, as well as the launch of POC clinical validation.

Nanjing Kaidi Medical Technology Co., Ltd. (formerly "Kaidi Biotechnology") was established in February 2015. Headquartered in the Nanjing Biopharmaceutical Valley, located in the National Jiangbei New Area of Nanjing, it is a leading cell therapy company with a globally advanced synthetic biology CAR discovery platform. The company owns world-leading autologous and allogeneic CAR discovery platforms and is committed to developing first-in-class cell drugs for unmet clinical needs in solid tumors using advanced synthetic biology technology platforms, as well as addressing the challenges and pain points of CAR-T clinical applications for solid tumors. The team has extensive and successful experience in large molecule and cell drug development. Currently, multiple globally leading cell therapy projects in the company’s R&D pipeline are in the clinical validation and IND application stages.

Dr. Dai Hongjiu, founder of Nanjing Kaidi Biotechnology Co., Ltd., expressed gratitude to both existing and new investors for their recognition and support of the company. Kaidi Biotechnology will remain committed to addressing unmet clinical needs, focusing on original innovation and advancing in the field of cell therapy. The company aims to build an outstanding team for the research and development of novel cell-based drugs, always prioritizing patients. It is dedicated to developing world-class cell therapies with the goal of benefiting millions of cancer patients as soon as possible. Kaidi Biotechnology is poised to become a rising star in the cell therapy sector, and we are confident about the future!

Mr. Wang Haining, founding partner of Longmen Capital, stated that Longmen Capital has long been focused on the development of new technologies in the pharmaceutical field and the growth of early-stage companies. Cell and gene therapy is one of our key areas of focus, especially in the treatment of solid tumors, where cell and gene therapy is expected to provide more effective and long-lasting solutions. Nanjing Kaidi Biotechnology Co., Ltd. is one of the few companies in China that focuses on CAR-T for solid tumors and continues to make breakthroughs. Its founding team has extensive experience in the research and development of CAR-T cell and gene therapies, combined with the team's industry experience in cell and gene therapy. We believe they can offer patients safer and more effective treatment options. For the Kaidi Medical project, we have made repeated investments, hoping to work hand-in-hand with Kaidi to jointly advance the global development of CAR-T cell and gene therapy drugs for solid tumors.

Mr. Wu Yinghua, Vice General Manager of Kangyuan Huiying, stated that Kaidi Biotechnology is an early-stage project in the cell and gene therapy sector invested by Kangyuan Huiying. With years of preclinical development experience and a proprietary synthetic biology platform, Dr. Dai's team has built a globally leading and highly differentiated product pipeline. We look forward to the company achieving key milestones in the coming year and gradually becoming a leading R&D platform in the CAR-T cell and gene therapy field, truly benefiting patients.

Longmen Capital is a professional venture capital institution in the pharmaceuticals industry, focusing on early-stage and growth-stage investments in pharmaceuticals and biotech innovation. The team members all have medical or biological backgrounds and possess years of experience in pharmaceutical investment and the industry.

Since its establishment in 2017, Longmen Capital has invested in more than 30 pharmaceutical companies, including Changfeng Pharmaceuticals, SiMicro Biologics, Sirnaomics, Jingyi Technology, Huode Biotech, Nanjing Kaidi Biotechnology Co., Ltd., and Zhongji Smart Pharma, with a fund management scale reaching 2 billion yuan.

Longmen Capital has always adhered to the principles of independent research and value discovery, being an early investor in many innovative companies, aiming to promote the industrialization of scientific and technological achievements with capital.

Kangyuan Huiying is a private equity investment institution focusing on three major fields: biomedicine, mass consumption, and intelligent manufacturing. The company's core management team has solid professional knowledge and extensive experience in various fields such as equity investment, capital operation, IPO planning, mergers and acquisitions, securities investment, and new energy industry investment. Since its establishment in 2017, Kangyuan Huiying has invested in more than 20 high-growth innovative enterprises, with a management scale of nearly 800 million yuan.

Nanjing Kaidi Biotechnology Co., Ltd. is a clinical-stage new drug research and development company. The company is committed to utilizing world-leading synthetic biology technology to develop novel cellular drugs that address unmet clinical needs for patients with solid tumors. Relying on its advanced synthetic biology technology platform—KD-SmCAR™, Kaidi Biotechnology has successfully developed multiple pipelines for first-class CAR-T new drugs targeting malignant solid tumors, including autologous and allogeneic universal CAR-T. The company has also expanded into next-generation pipelines such as CAR-NK and CAR-MO. To date, it has filed over thirty CAR-related patent applications in both China and the U.S., with ten patents already granted, placing the company at a leading level in the global CAR-T industry. Notably, the core pipeline KD-025 has been granted its first patents in both China and the U.S.

Preclinical research results of KD-025 CAR-T product targeting NKG2DL for indications such as liver cancer and glioma were successively published inInternational authoritative journals on cancer immunotherapy, "Journal for ImmunoTherapy of Cancer" and "Cancer Immunology Research," and the American Society of Clinical Oncology (ASCO) Annual MeetingPublished. Nanjing Kaidi Biotechnology Co., Ltd. is currently conducting KD-025 CAR-T Proof of Concept (POC) clinical trials at multiple renowned clinical centers in China. Several clinical infusions have been completed with no significant toxic side effects, demonstrating that the product is safe and effective. Meanwhile, Kaidi is rapidly advancing the KD-025 CAR-T IND application and multiple POC clinical trials for novel dual-targeting CAR-T therapies through strategic collaborations. Additionally, Kaidi Medical is progressing in the development of a synthetic biology living drug platform, which is expected to achieve breakthroughs in several fully synthetic living drugs in the near future.